IOL Chemicals And Pharmaceuticals Ltd.
Snapshot View

671.35 +7.05 ▲1.1%

02 August 2021, 04:00:00 P.M.
Volume: 45,341

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.iolcp.com
Financial Indicators
Market Cap 3,899.81 Cr.
Earnings per share (EPS) 75.73 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 8.77 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 214.70 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.09 Calculated using Price: 664.30
Dividend Yield 0.30 Period Ending 2020-03
No. of Shares Subscribed 5.87 Cr. 58,705,502 Shares
FaceValue 10
Company Profile

IOL Chemicals and Pharmaceuticals (IOLCP) is a leading organic chemicals manufacturers and suppliers. They are Indian manufacturer of industrial chemicals & bulk drugs for over two decades, by pursuing & implementing the highest standards of excellence in their operations, they have nurtured their capabilities by delivering consistent results and have earned the admiration of customers and stakeholders alike.

IOLCP has attained a front line position in the domestic segment and is thus contemplating to widen its horizon through global penetration. It has overseas customers from various countries like Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt and many others.

IOLCP is therefore moving ahead with its vision to develop global strategic alliances with quality leaders and expand into new markets.

Product range of the company includes:

  • Acetic AcidWith a production capacity of 6.5 million metric tonnes, Acetic Acid is a significant chemical reagent & industrial chemical with a wide spectrum of applications.
  • Ethyl Acetate Ethyl Acetate is a significant industrial solvent with diverse industrial applications.
  • Acetic AnhydrideAcetic Anhydride is a well-known acid anhydride that is widely used in pharmaceutical & agrochemical industries.
  • Isobutyl BenzeneThis specialty chemical is used as an intermediate in Ibuprofen and other anti-inflammatory analgesic bulk drug
  • Mono Chloro Acetic AcidAlso know as Chloro Acetic Acid it is used in agrochemicals, pesticides, insecticides, organic chemicals etc.
  • Acetyl ChlorideAcetyl Chlorideis is colourless, near to pale yellow liquid that is used in perfume, dye, chemical, pharmaceutical bulk drugs and intermediates.
  • Ibuprofen A non-steroidal anti-inflammatory drug, Ibuprofen is used in the treatment of a variety of ailments such as arthritis, dysmenorrhoea, and is also used an analgesic.  

Clientele:

They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, CIPLA, Flex Industries, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phosphate, & Avon Organics etc.

Awards & Achievements:

  • IOL Chemicals & Pharmaceuticals has consecutively been bestowed with the 2nd Prize in Chemical Sector-National Energy Conservation Award 2007, by the Ministry of Power, Government of India for the third time in a row for its efforts made towards new technology implementation to conserve the energy resources of the company.
  • IOLCP has also won Kamla Dial Gold Standard for North-West Qual Tech Standards-2006 conducted by Qimpro College Mumbai.
  • One star Export House Status Award.
  • National Energy Conservation Award 2007.
  • National Energy Conservation Award 2006.
  • National Energy Conservation Award 2005.
  • One star export House Status Award.
  • Halal Certification.
  • Kosher Certification.
  • USFDA Certification.
  • EDQM Certification.

Future Plans:

  • Chemicals Expansion - The company has planned for increasing the capacity of Acetic Acid from 50000 TPA to 66000 TPA, Ethyl Acetate from 33000 TPA to 36000 TPA & Capacity of Acetic Anhydride from 12000 TPA to 18000 TPA.
  • Pharma Expansion -  IOLCP recently boosted its Ibuprofen plant capacity to 3600 TPA from 1800 TPA and to further expand the capacity to 6000 TPA.
  • PPI's - The company has planned for installation of new manufacturing facilities of following PPIs:-Rabeprazole -Lansoprazole -Omeprazole -Pantoprazole -Esomeprazole. With annual installed capacity of 360 MT, the commercial production will start by the end of 2008.
  • Co-generation Power Plant  - To meet out its enhanced energy requirement and to become self reliance the company has also proposed for another captive co-generation plant with additional capacity of 13 MW in addition to the existing cogeneration plant of 4 MW capacity.
  • Forward Integration - The company has planned for adding two more products i.e. Mono Chloro Acetic Acid(MCA) with a capacity of 6600 TPA & Acetyl Chloride with a capacity of 4800 TPA , using Acetic Anhydride & Acetic Acid as a raw material.
  • Backward Integration - The company has planned for setting up plant for Iso-butyl Benzene(IBB) with a capacity of 6000 TPA which will be the raw material for the manufacturing of Ibuprofen.
  • Research & Development  - To develop new Molecules and process development

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.06%
1 Week
-2.84%
1 Month
+3.83%
3 Month
+13.42%
6 Month
-1.13%
1 Year
-13.95%
2 Year
+245.61%
5 Year
+348.31%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 2.85 0.95 1.85 -34.14 -20.72 2.50 13.70 69.54 56.93
Return on Capital Employed (%) 8.72 10.55 11.48 -2.78 3.68 11.57 15.03 55.53 68.09
Return on Assets (%) 0.74 0.22 0.45 -9.24 -5.43 0.59 3.34 25.50 30.59

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 174 173 209 207 185 189 216 474 814
Non Curr. Liab. 288 326 255 286 304 294 280 211 80
Curr. Liab. 226 229 277 209 283 328 351 325 459
Minority Int.
Equity & Liab. 688 727 742 702 772 811 847 1,010 1,353
Non Curr. Assets 488 476 460 418 416 396 416 458 505
Curr. Assets 200 251 281 283 357 415 431 552 848
Misc. Exp. not W/O
Total Assets 688 727 742 702 772 811 847 1,010 1,353

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 471 482 564 385 580 711 983 1,685 1,894
Other Income 2 3 1 1 1 1 6 10 16
Total Income 473 484 565 386 582 712 990 1,696 1,910
Total Expenditure -402 -392 -468 -373 -529 -608 -864 -1,276 -1,321
PBIDT 71 92 97 13 53 103 126 420 590
Interest -43 -57 -60 -59 -61 -68 -64 -51 -21
Depreciation -24 -31 -32 -29 -30 -30 -30 -32 -36
Taxation 1 -1 -2 9 -1 -1 -4 -99 -172
Exceptional Items
PAT 5 2 3 -67 -40 5 28 237 361

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 55 53 78 -47 18 83 120 273 471
Cash Fr. Inv. -87 -18 -12 -5 -27 -23 -50 -63 -185
Cash Fr. Finan. 23 -32 -66 50 9 -60 -70 -197 -272
Net Change -9 3 1 -2 0 1 -1 13 15
Cash & Cash Eqvt 11 14 15 13 1 2 1 13 28

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 41.89 41.89 41.89 41.89 43.69 43.69 43.69 43.69 43.69
Public 58.11 58.11 58.11 58.11 56.31 56.31 56.31 56.31 56.31
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Notice published in newspapers regarding loss of Share Certificates
Thu, 29 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of lost share certificates
Mon, 19 Jul 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of analyst / investor Meet

Technical Scans View Details

Fri, 30 Jul 2021
Opening at High Opening at High
Closing Near 200 SMA Closing Near 200 SMA
ROC Trending Down ROC Trending Down
Thu, 29 Jul 2021
Closing Near 200 SMA Closing Near 200 SMA
Wed, 28 Jul 2021
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.45 +0.1%
Divi's Laboratories Ltd. 129,702.64 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,701.80 -0.2%
Cipla Ltd. 74,235.31 921.80 +0.2%
Cadila Healthcare Ltd. 59,986.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,049.00 +0.4%
Aurobindo Pharma Ltd. 53,701.27 918.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.87 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 918.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.05 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 918.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 918.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 918.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 918.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 918.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 918.00 +0.1%